Download PDF
Horm Metab Res 2014; 46(10): 685-690
DOI: 10.1055/s-0034-1382078
Endocrine Care
© Georg Thieme Verlag KG Stuttgart · New York

Relationship Between Serum Levels of Angiopoietin-Related Growth Factor and Metabolic Risk Factors

T. Ebert
1   Department of Endocrinology and Nephrology, University of Leipzig, Leipzig, Germany
2   IFB AdiposityDiseases, Leipzig University Medical Center, Leipzig, Germany
,
S. Kralisch
1   Department of Endocrinology and Nephrology, University of Leipzig, Leipzig, Germany
2   IFB AdiposityDiseases, Leipzig University Medical Center, Leipzig, Germany
,
U. Loessner
1   Department of Endocrinology and Nephrology, University of Leipzig, Leipzig, Germany
2   IFB AdiposityDiseases, Leipzig University Medical Center, Leipzig, Germany
,
B. Jessnitzer
1   Department of Endocrinology and Nephrology, University of Leipzig, Leipzig, Germany
,
M. Stumvoll
1   Department of Endocrinology and Nephrology, University of Leipzig, Leipzig, Germany
,
M. Fasshauer
1   Department of Endocrinology and Nephrology, University of Leipzig, Leipzig, Germany
2   IFB AdiposityDiseases, Leipzig University Medical Center, Leipzig, Germany
,
A. Tönjes
1   Department of Endocrinology and Nephrology, University of Leipzig, Leipzig, Germany
2   IFB AdiposityDiseases, Leipzig University Medical Center, Leipzig, Germany
› Author Affiliations
Further Information

Publication History

received 13 January 2014

accepted 04 June 2014

Publication Date:
10 July 2014 (online)

Also available at
    Permissions and Reprints

Abstract

Angiopoietin-related growth factor (AGF, also known as angiopoietin-like protein 6) has been introduced as a novel hepatocyte-derived factor, which antagonizes obesity and insulin resistance in mice. However, human studies show conflicting results and are limited to a small cohort of patients. In the current study, we therefore sought to investigate AGF serum levels in a large metabolically well-characterized cohort. AGF serum concentrations were determined by commercial enzyme-linked immunosorbent assay in 697 patients of a cohort from Eastern Germany (Sorbs). Correlations of AGF serum levels with clinical and biochemical measures of glucose and lipid metabolism, as well as markers of renal function, were investigated. In nondiabetic subjects (n=627), AGF was positively correlated with markers of insulin resistance and negatively correlated with high-density lipoprotein cholesterol in univariate analyses (p<0.05). After adjustment for age, gender, and body mass index, none of these factors remained independently associated with AGF, neither in nondiabetic subjects nor in patients with type 2 diabetes mellitus (T2DM) (n=70). However, we confirmed existing data of significantly higher AGF concentrations in patients with T2DM as compared to controls in this large cohort. Circulating AGF is elevated in subjects with T2DM and related to the type of antidiabetic treatment, but is not independently associated with anthropometric parameters, indices of insulin sensitivity and secretion, or a number of other adipokines.

Key words

AGF - angptl6 - Sorbs - diabetes

Supporting Information

 

  • References

  • 1 Mozumdar A, Liguori G. Persistent Increase of Prevalence of Metabolic Syndrome Among U.S. Adults: NHANES III to NHANES 1999–2006. Diabetes Care 2011; 34: 216-219
    CrossrefPubMedGoogle Scholar
  • 2 Fasshauer M, Paschke R. Regulation of adipocytokines and insulin resistance. Diabetologia 2003; 46: 1594-1603
    CrossrefPubMedGoogle Scholar
  • 3 Trujillo ME, Scherer PE. Adipose tissue-derived factors: impact on health and disease. Endocr Rev 2006; 27: 762-778
    CrossrefPubMedGoogle Scholar
  • 4 Hotamisligil GS, Shargill NS, Spiegelman BM. Adipose expression of tumor necrosis factor-alpha: direct role in obesity-linked insulin resistance. Science 1993; 259: 87-91
    CrossrefPubMedGoogle Scholar
  • 5 Kharitonenkov A, Shiyanova TL, Koester A, Ford AM, Micanovic R, Galbreath EJ, Sandusky GE, Hammond LJ, Moyers JS, Owens RA, Gromada J, Brozinick JT, Hawkins ED, Wroblewski VJ, Li DS, Mehrbod F, Jaskunas SR, Shanafelt AB. FGF-21 as a novel metabolic regulator. J Clin Invest 2005; 115: 1627-1635
    CrossrefPubMedGoogle Scholar
  • 6 Oike Y, Akao M, Yasunaga K, Yamauchi T, Morisada T, Ito Y, Urano T, Kimura Y, Kubota Y, Maekawa H, Miyamoto T, Miyata K, Matsumoto S, Sakai J, Nakagata N, Takeya M, Koseki H, Ogawa Y, Kadowaki T, Suda T. Angiopoietin-related growth factor antagonizes obesity and insulin resistance. Nat Med 2005; 11: 400-408
    CrossrefPubMedGoogle Scholar
  • 7 Oike Y, Ito Y, Maekawa H, Morisada T, Kubota Y, Akao M, Urano T, Yasunaga K, Suda T. Angiopoietin-related growth factor (AGF) promotes angiogenesis. Blood 2004; 103: 3760-3765
    CrossrefPubMedGoogle Scholar
  • 8 Ebert T, Bachmann A, Lossner U, Kratzsch J, Bluher M, Stumvoll M, Fasshauer M. Serum levels of angiopoietin-related growth factor in diabetes mellitus and chronic hemodialysis. Metabolism 2009; 58: 547-551
    CrossrefPubMedGoogle Scholar
  • 9 Stepan H, Ebert T, Schrey S, Reisenbuchler C, Stein S, Lossner U, Bluher M, Stumvoll M, Kratzsch J, Faber R, Fasshauer M. Serum Levels of Angiopoietin-Related Growth Factor Are Increased in Preeclampsia. Am J Hypertens 2009; 22: 314-318
    CrossrefPubMedGoogle Scholar
  • 10 Namkung J, Koh SB, Kong ID, Choi J-W, Yeh B-I. Serum levels of angiopoietin-related growth factor are increased in metabolic syndrome. Metabolism 2011; 60: 564-568
    CrossrefPubMedGoogle Scholar
  • 11 Tonjes A, Zeggini E, Kovacs P, Bottcher Y, Schleinitz D, Dietrich K, Morris AP, Enigk B, Rayner NW, Koriath M, Eszlinger M, Kemppinen A, Prokopenko I, Hoffmann K, Teupser D, Thiery J, Krohn K, McCarthy MI, Stumvoll M. Association of FTO variants with BMI and fat mass in the self-contained population of Sorbs in Germany. Eur J Hum Genet 2010; 18: 104-110
    CrossrefPubMedGoogle Scholar
  • 12 American Diabetes Association. Diagnosis and Classification of Diabetes Mellitus. Diabetes Care 2009; 32: S62-S67
    CrossrefPubMedGoogle Scholar
  • 13 Levey AS, Stevens LA, Schmid CH, Zhang YL, Castro AF, Feldman HI, Kusek JW, Eggers P, Van Lente F, Greene T, Coresh J. A new equation to estimate glomerular filtration rate. Ann Intern Med 2009; 150: 604-612
    CrossrefPubMedGoogle Scholar
  • 14 Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 1985; 28: 412-419
    Google Scholar
  • 15 Matsuda M, DeFronzo RA. Insulin sensitivity indices obtained from oral glucose tolerance testing: comparison with the euglycemic insulin clamp. Diabetes Care 1999; 22: 1462-1470
    CrossrefPubMedGoogle Scholar
  • 16 Stumvoll M, Haeften TV, Fritsche A, Gerich J. Oral Glucose Tolerance Test Indexes for Insulin Sensitivity and Secretion Based on Various Availabilities of Sampling Times. Diabetes Care 2001; 24: 796-797
    CrossrefPubMedGoogle Scholar
  • 17 Boztosun A, Deveci K, Klçl F, Söylemez MS, Muhtaroglu S, Müderris II. Serum Levels of Angiopoietin-Related Growth Factor (AGF) Are Increased in Polycystic Ovary Syndrome. Journal of Investigative Medicine 2012; 60: 813-817
    PubMedGoogle Scholar
  • 18 Abdullah B, Deveci K, Atilgan R, Kiliçli F, Söylemez MS. Serum angiopoietin-related growth factor (AGF) levels are elevated in gestational diabetes mellitus and associated with insulin resistance. Ginekol Pol 2012; 83: 749-753
    PubMedGoogle Scholar
  • 19 Oike Y, Yasunaga K, Ito Y, Matsumoto S, Maekawa H, Morisada T, Arai F, Nakagata N, Takeya M, Masuho Y, Suda T. Angiopoietin-related growth factor (AGF) promotes epidermal proliferation, remodeling, and regeneration. Proc Natl Acad Sci USA 2003; 100: 9494-9499
    CrossrefPubMedGoogle Scholar
  • 20 Zheng J, Umikawa M, Cui C, Li J, Chen X, Zhang C, Huynh H, Kang X, Silvany R, Wan X, Ye J, Cantó AP, Chen S-H, Wang H-Y, Ward ES, Zhang CC. Inhibitory receptors bind ANGPTLs and support blood stem cells and leukaemia development. Nature 2012; 485: 656-660
    CrossrefPubMedGoogle Scholar
  • 21 Stein S, Stepan H, Kratzsch J, Verlohren M, Verlohren HJ, Drynda K, Lossner U, Bluher M, Stumvoll M, Fasshauer M. Serum fibroblast growth factor 21 levels in gestational diabetes mellitus in relation to insulin resistance and dyslipidemia. Metabolism 2010; 59: 33-37
    CrossrefPubMedGoogle Scholar
  • 22 Kralisch S, Tönjes A, Krause K, Richter J, Lossner U, Kovacs P, Ebert T, Blüher M, Stumvoll M, Fasshauer M. Fibroblast growth factor-21 serum concentrations are associated with metabolic and hepatic markers in humans. J Endocrinol 2013; 216: 135-143
    CrossrefPubMedGoogle Scholar
  • 23 Fasshauer M, Waldeyer T, Seeger J, Schrey S, Ebert T, Kratzsch J, Lössner U, Blüher M, Stumvoll M, Faber R, Stepan H. Circulating high-molecular-weight adiponectin is upregulated in preeclampsia and is related to insulin sensitivity and renal function. Eur J Endocrinol 2008; 158: 197-201
    CrossrefPubMedGoogle Scholar
  • 24 Considine RV, Sinha MK, Heiman ML, Kriauciunas A, Stephens TW, Nyce MR, Ohannesian JP, Marco CC, McKee LJ, Bauer TL, Caro JF. Serum Immunoreactive-Leptin Concentrations in Normal-Weight and Obese Humans. New Eng J Med 1996; 334: 292-295
    CrossrefPubMedGoogle Scholar
  • 25 Fisher FM, Chui PC, Antonellis PJ, Bina HA, Kharitonenkov A, Flier JS, Maratos-Flier E. Obesity Is a Fibroblast Growth Factor 21 (FGF21)-Resistant State. Diabetes 2010; 59: 2781-2789
    CrossrefPubMedGoogle Scholar
  • 26 Xia G, Fang M, He Y, Zhang T, Jin Y, Jiang L. Alterations of angiopoietin-related growth factor (Angptl6) during pregnancy and in pre-eclampsia. J Obstet Gynaecol Res 2013; 39: 1137-1141
    CrossrefPubMedGoogle Scholar